Medexus Pharmaceuticals Future Growth
Future criteria checks 5/6
Medexus Pharmaceuticals is forecast to grow earnings and revenue by 50.3% and 9.3% per annum respectively. EPS is expected to grow by 45.7% per annum. Return on equity is forecast to be 29% in 3 years.
Key information
50.3%
Earnings growth rate
45.7%
EPS growth rate
| Pharmaceuticals earnings growth | 18.0% |
| Revenue growth rate | 9.3% |
| Future return on equity | 29.0% |
| Analyst coverage | Good |
| Last updated | 18 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 116 | 16 | N/A | 28 | 3 |
| 3/31/2026 | 99 | 1 | N/A | 19 | 4 |
| 3/31/2025 | 103 | 3 | N/A | 16 | 6 |
| 6/30/2024 | 109 | 1 | 22 | 23 | N/A |
| 3/31/2024 | 113 | 0 | 18 | 19 | N/A |
| 12/31/2023 | 116 | 6 | 21 | 21 | N/A |
| 9/30/2023 | 119 | 5 | 13 | 13 | N/A |
| 6/30/2023 | 117 | 3 | 6 | 7 | N/A |
| 3/31/2023 | 108 | 1 | -2 | -1 | N/A |
| 12/31/2022 | 100 | -11 | -3 | -2 | N/A |
| 9/30/2022 | 92 | -11 | -3 | -1 | N/A |
| 6/30/2022 | 82 | 2 | 0 | 2 | N/A |
| 3/31/2022 | 77 | -3 | -9 | -1 | N/A |
| 12/31/2021 | 74 | -8 | -17 | -1 | N/A |
| 9/30/2021 | 77 | -20 | -18 | -1 | N/A |
| 6/30/2021 | 77 | -31 | -21 | -5 | N/A |
| 3/31/2021 | 80 | -28 | -6 | 5 | N/A |
| 12/31/2020 | 79 | -19 | -1 | 0 | N/A |
| 9/30/2020 | 69 | -9 | 1 | 1 | N/A |
| 6/30/2020 | 64 | -7 | 1 | 1 | N/A |
| 3/31/2020 | 56 | -5 | -3 | -2 | N/A |
| 12/31/2019 | 47 | -4 | -1 | 0 | N/A |
| 9/30/2019 | 45 | -3 | -1 | 0 | N/A |
| 6/30/2019 | 36 | -6 | -2 | -1 | N/A |
| 3/31/2019 | 25 | -5 | -1 | -1 | N/A |
| 12/31/2018 | 17 | -5 | -3 | -2 | N/A |
| 9/30/2018 | 9 | -5 | -1 | -1 | N/A |
| 6/30/2018 | 8 | -2 | -2 | -2 | N/A |
| 3/31/2018 | 8 | -3 | N/A | -3 | N/A |
| 12/31/2017 | 8 | -3 | N/A | -3 | N/A |
| 9/30/2017 | 7 | -3 | N/A | -4 | N/A |
| 6/30/2017 | 6 | -3 | N/A | -4 | N/A |
| 3/31/2017 | 5 | -1 | N/A | -1 | N/A |
| 12/31/2016 | 4 | 1 | N/A | 1 | N/A |
| 9/30/2016 | 3 | 1 | N/A | 1 | N/A |
| 6/30/2016 | 3 | 1 | N/A | 1 | N/A |
| 3/31/2016 | 3 | -2 | N/A | -1 | N/A |
| 12/31/2015 | 3 | -4 | N/A | -3 | N/A |
| 9/30/2015 | 2 | -4 | N/A | -3 | N/A |
| 6/30/2015 | 2 | -5 | N/A | -3 | N/A |
| 3/31/2015 | 2 | -4 | N/A | -4 | N/A |
| 12/31/2014 | 3 | -4 | N/A | -3 | N/A |
| 9/30/2014 | 3 | -4 | N/A | -3 | N/A |
| 6/30/2014 | 4 | -3 | N/A | -3 | N/A |
| 3/31/2014 | 3 | -3 | N/A | -1 | N/A |
| 12/31/2013 | 4 | -2 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: P731's forecast earnings growth (50.3% per year) is above the savings rate (0.8%).
Earnings vs Market: P731's earnings (50.3% per year) are forecast to grow faster than the German market (20.1% per year).
High Growth Earnings: P731's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: P731's revenue (9.3% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: P731's revenue (9.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: P731's Return on Equity is forecast to be high in 3 years time (29%)